- Conditions
- Axial Spondyloarthritis
- Interventions
- Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg, Golimumab 50 mg
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 347 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 11
- States / cities
- Peoria, Arizona • St. Petersburg, Florida • Tampa, Florida + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–82
of 82
matching trials from the live ClinicalTrials.gov search.
- Conditions
- COVID-19; Immunity
- Interventions
- No intervention
- Other
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 38 participants
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- San Dimas, California
- Conditions
- Feeding Disorders, Feeding and Eating Disorders, Avoidant/Restrictive Food Intake Disorder
- Interventions
- Intensive Multidisciplinary Feeding Intervention (IMFI)-Standard of Care, Intensive Multidisciplinary Feeding Intervention (IMFI) standard of care + rapid tube weaning
- Behavioral
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Months to 6 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Low Back Pain, Pain, Pain, Intractable
- Interventions
- Cognitive behavioral therapy, Pain self-management program, Co-Analgesic Therapy, Opioid Analgesics
- Behavioral · Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 242 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Moderate-to-Severe Atopic Dermatitis
- Interventions
- Rezpegaldesleukin, Placebo
- Drug
- Lead sponsor
- Nektar Therapeutics
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 510 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • North Little Rock, Arkansas • Fountain Valley, California + 15 more
- Conditions
- Moderate to Severe Atopic Dermatitis
- Interventions
- Rezpegaldesleukin, Placebo
- Drug
- Lead sponsor
- Nektar Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 396 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 28
- States / cities
- Bryant, Arkansas • Fountain Valley, California • Los Angeles, California + 22 more
- Conditions
- Military Operational Stress Reaction, Malnutrition (Calorie), Weight Loss, Muscle Wasting
- Interventions
- Protein, High-Protein, and Control
- Dietary Supplement
- Lead sponsor
- United States Army Research Institute of Environmental Medicine
- Federal
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 71 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Marine Corps Base Camp Lejeune, North Carolina
- Conditions
- Prostate Cancer
- Interventions
- PSMA-PET CT
- Diagnostic Test
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 4
- States / cities
- Los Angeles, California • San Francisco, California • New York, New York + 1 more
- Conditions
- Feeding Disorders, Specific Phobia
- Interventions
- Behavioral Intervention, d-cycloserine (DCS), Placebo
- Behavioral · Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Months to 6 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Migraine Disorders, Heart Septal Defects, Atrial
- Interventions
- PFO Closure with Premere investigational device., Medical management/current medications per standard of care by personal physician.
- Device · Drug
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 37
- States / cities
- Scottsdale, Arizona • Newport Beach, California • Sacramento, California + 31 more